Abstract
Introduction

41
Up to 350 million individuals worldwide are currently chronically infected with and control [16] [17] [18] . However, both type I/II interferons were shown to promote 70 PD-L1 expression in hepatocytes, which may induce T cell apoptosis [19] [20] [21] . 71 Therefore, further elucidating the mechanism of hepatic PD-L1 expression induced by 72 IFN-α/γ and its role in T cell response will shed light on the underlying mechanism of 73 antiviral T cell tolerance and the unique immunological properties of liver.
74
Here, we aimed to explore the mechanism of PD-L1 upregulation in hepatocytes 
Materials and Methods
80
Cell Lines
81
The human hepatic cell line L02 originated from normal human liver tissue of PD-L1 promoter and Stat1-specific siRNA are listed in Table 1 . and HBe Ag, and HBV DNA copies) were performed as described previously [24] .
111
119
IFN-α and IFN-γ treatment in mice 120
Six-week-old male BALB/c mice were purchased from Vital River Laboratories.
121
Mice were randomly divided into 5 groups (n=5/group) and injected with PBS, IFN-α sacrificed at week 9 for antiviral T cell analysis and virology assessment.
138
Statistical analysis
139
All data were presented as mean ± SD, and significance was determined by 
Results
150
IFN-α/γ induce PD-L1 expression in hepatocytes 151
We first tested whether IFN-α and IFN-γ could affect PD-L1 expression in 152 hepatocytes. As shown in Figure 1A , PD-L1 expression was increased by IFN-γ in a 153 dose-dependent manner from 10 to 800 U/ml 48 h after treatment. Similar results
154
were observed for IFN-α (Fig 1B) . In vivo experiment, BALB/c mice were PD-L1 levels in BALB/c mice ( Fig 1C) .
158
We then determine if IFN-α/γ upregulate the expression of PD-L1 by affect its 159 transcription level. Real-time PCR analysis showed that IFN-γ pronouncedly 160 increased PD-L1 mRNA levels ( Fig 1D) . Similar results were observed for IFN-α (Fig   161   1E ). 
176
The PD-L1 promoter sequence was subjected to bioinformatics analysis to the other transcription factors (Fig 2B) . Same results were obtained for IFN-α 183 treatment ( Fig 2C) . The protein expression of Stat1 and its phosphorylation were also 184 stimulated by IFN-γ or IFN-α ( Fig 2D) . As shown in Figure 2E and 2F, Stat1 obvious increase in the wild-type but not mutant PD-L1 promoter activity (~ 3.5-fold)
187
(P < 0.001) and significant elevation of cell membrane PD-L1 levels. These results
188
indicate that IFN-α/γ upregulates the key PD-L1 transcription factor Stat1. IFN-γ-induced PD-L1 promoter activation (Fig 3B) . Similar results were observed for 212 IFN-α (Fig 3C and 3D) . depletion by siRNA or inhibition by fludarabine (Fig 4A and 4B) . Similar results were 225 observed in total PD-L1 mRNA levels and protein levels (Fig 4C) . In addition, experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 using t-tests.
270
Significant decreases in serum HBV DNA and HBsAg levels were observed in 271 gp96 vaccine-immunized mice treated with anti-PD-1 mAb compared to untreated 272 mice (both P < 0.05) (Fig 6A and 6B) . Mice receiving the combined treatment of (Fig 6C) . Moderate elevation of the serum ALT levels was observed in 277 anti-PD-1 mAb-treated and gp96 vacccine-immunized mice (Fig 6D) . Taken together, experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 using t-tests. 
